Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
2984933
Reference Type
Journal Article
Title
Transcatheter closure of patent foramen ovale without an implant: initial clinical experience
Author(s)
Sievert, H; Fischer, E; Heinisch, C; Majunke, N; Roemer, A; Wunderlich, N
Year
2007
Is Peer Reviewed?
Yes
Journal
Circulation
ISSN:
0009-7322
EISSN:
1524-4539
Volume
116
Issue
15
Page Numbers
1701-1706
Language
English
PMID
17893276
DOI
10.1161/CIRCULATIONAHA.107.696310
Web of Science Id
WOS:000250007700008
Abstract
BACKGROUND:
Currently available catheter techniques for closure of a patent foramen ovale (PFO) rely on the placement of an implantable closure device. The objective of the Paradigm I study was to evaluate the safety and feasibility of transcatheter closure of PFO using radiofrequency energy without an implanted device in patients with cryptogenic stroke or transient ischemic attack.
METHODS AND RESULTS:
Thirty patients were enrolled (15 females; mean age 48 years). Mean PFO size was 8.5+/-2.7 mm. Technical success (ie, successful application of radiofrequency energy) was achieved in 27 patients. The remaining 3 patients received an implantable closure device. All 30 patients were free from serious procedure-related adverse events. No recurrent strokes, deaths, or perforations occurred as a result of the procedure. The mean follow-up was 6 months, and 13 (43%) of the 30 patients experienced PFO closure after the first procedure. Nine of the patients whose PFOs remained patent after the first procedure elected to receive a second procedure using radiofrequency. The PFO was closed for 6 of those patients after the second procedure, which resulted in a secondary closure rate of 63%.
CONCLUSIONS:
This study demonstrates that transcatheter closure of an intracardiac defect without a permanent implant is technically feasible. Achievement of improved primary closure rates through technique and device modifications will warrant randomized clinical comparison to permanently implanted devices.
Keywords
heart defects; congenital; stroke; embolism; catheterization; catheter ablation
Tags
PFAS
•
Additional PFAS (formerly XAgency)
•
PFAS 150
Literature Search August 2019
PubMed
Web of Science
Not prioritized for screening
Perfluorooctanesulfonic acid
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity